Connor Clark & Lunn Investment Management Ltd. Has $581,000 Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 106.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 171,332 shares of the company’s stock after buying an additional 88,224 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.11% of Xeris Biopharma worth $581,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Legato Capital Management LLC purchased a new position in shares of Xeris Biopharma in the 4th quarter worth approximately $482,000. Barclays PLC lifted its holdings in Xeris Biopharma by 87.8% during the third quarter. Barclays PLC now owns 324,472 shares of the company’s stock worth $925,000 after acquiring an additional 151,685 shares during the period. Geode Capital Management LLC boosted its position in Xeris Biopharma by 2.9% in the third quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company’s stock worth $9,502,000 after purchasing an additional 93,091 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Xeris Biopharma by 30.3% in the third quarter. Principal Financial Group Inc. now owns 102,469 shares of the company’s stock valued at $292,000 after acquiring an additional 23,843 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new position in shares of Xeris Biopharma during the 3rd quarter valued at $44,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on XERS shares. Piper Sandler restated a “neutral” rating and set a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Leerink Partners boosted their price target on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Friday, March 7th. HC Wainwright reissued a “buy” rating and issued a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Craig Hallum upped their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research note on Friday, March 7th. Finally, Jefferies Financial Group restated a “buy” rating and set a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.92.

Insider Buying and Selling

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the company’s stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $5.43, for a total transaction of $217,200.00. Following the transaction, the insider now owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. This represents a 2.87 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.56% of the stock is currently owned by company insiders.

Xeris Biopharma Trading Up 7.0 %

Shares of NASDAQ:XERS opened at $5.81 on Friday. Xeris Biopharma Holdings, Inc. has a 12-month low of $1.69 and a 12-month high of $5.92. The stock has a market capitalization of $894.39 million, a price-to-earnings ratio of -12.91 and a beta of 2.32. The stock has a fifty day simple moving average of $3.88 and a two-hundred day simple moving average of $3.41.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.